ReviewCurrent atherosclerosis reports2026
The Role of Furin in Hallmarks of Aneurysms: A Focus On Its Substrates.
Review in Current atherosclerosis reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
purpose of reviewAn aneurysm is a frequently occurring and potentially life-threatening cardiovascular disease. However, limited clinical therapeutic drugs are available. Here, we aimed to provide a framework for aneurysm treatment by targeting Furin. RECENT
findingsOur recent study reported, for the first time, that several Furin variants are found in patients with aneurysm, indicating the important role of Furin in aneurysm. Given that Furin is an important endoproteolytic enzyme that modulates the biochemical activity of proproteins involved in aneurysm formation and progression, interfering with Furin could be a promising strategy for aneurysm treatment. Since several Furin substrates like TGF-β1, NOTCH, IGF1R/IR and MMPs/ADAMs are closely associated with the hallmarks of aneurysm, Furin is a potential target for aneurysm treatment. However, significant gaps remain in our understanding of Furin in the different biological the hallmarks of aneurysms, due to the different role of Furin substrates in regulating the hallmarks of aneurysm. Further research is needed to clarify how the summarized interfering strategies targeting Furin impact on the aneurysm formation and progression in vivo.
Indexed as
Identifiers
42446824What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.